Effects of Vitamin D Supplementation on 24-Hour Blood Pressure in Patients with Low 25-Hydroxyvitamin D Levels: A Randomized Controlled Trial.

What Was Tested

This randomized controlled trial looks at Vitamin D, K2, Magnesium and Zinc in the context of low blood pressure and orthostatic hypotension.

The researchers addressed this issue in a post hoc analysis of the double-blind, randomized, placebo-controlled Styrian Vitamin D Hypertension Trial (2011−2014) with 200 hypertensive patients with 25(OH)D levels <30 ng/mL.

Who Took Part

The abstract describes 200 patients taking part.

How the Study Was Run

The researchers set it up as a randomized, double-blind and placebo-controlled study.

Because people in this Vitamin D, K2, Magnesium and Zinc study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

As a double-blind Vitamin D, K2, Magnesium and Zinc study, the assignments were hidden from both participants and investigators until the end.

A placebo (an inactive look-alike) gave the Vitamin D, K2, Magnesium and Zinc group a baseline to be compared against.

What Was Measured

The researchers addressed this issue in a post hoc analysis of the double-blind, randomized, placebo-controlled Styrian Vitamin D Hypertension Trial (2011−2014) with 200 hypertensive patients with 25(OH)D levels <30 ng/mL.

PubMed files the paper under topics including Blood Pressure, Calcifediol, Cholecalciferol, Dietary Supplements, Hypertension, Vitamin D and Vitamin D Deficiency.

Author keywords: cardiovascular risk.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Vitamin D, K2, Magnesium and Zinc in 200 patients in people with low blood pressure and orthostatic hypotension.

The publication is from 2022 (Nutrients), a journal based in Switzerland.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, Low blood pressure and orthostatic hypotension research.